Weekly Newsletter - 11.13.2024

SPONSORED BY

EDITOR’S PICK🎯 

Faster, Smarter, and More Effective: AI-Driven Sales Enablement

Laura Keith, CEO of Hive Perform, champions the transformative power of AI in sales onboarding. In a recent post, she highlights the success story of Fospha, one of Hive Perform's earliest adopters. 3 outcomes in record time.

INDUSTRY NEWS📰

Novo Nordisk's Wegovy Sales Exceed Expectations

Novo Nordisk’s Wegovy sales hit $2.5B in Q3, beating expectations and easing concerns about demand in the obesity drug market. However, group sales fell slightly short, with weaker Ozempic performance. Shares surged 9% before adjusting on slower growth projections for 2024.

High demand continues to outpace supply, even after tripling Wegovy production. CEO Lars Fruergaard Jorgensen highlighted ongoing challenges in meeting patient needs. The company is doubling down on its obesity drug portfolio, with new data from its CagriSema trial expected soon.

Novo projects 23%-27% sales growth this year, maintaining its lead in a market estimated to hit $150B by 2030, as it competes with Eli Lilly for dominance.

INDUSTRY INSIGHTS🌐

US Healthcare Companies Eye India's Growing Market Potential

U.S. healthcare companies are increasingly investing in India's booming market, projected to reach $638 billion by 2025. Progressive policies, cost-effective manufacturing, and strategic partnerships offer significant opportunities. However, challenges like cultural differences and infrastructure gaps exist. Adapting strategies and leveraging India's advantages are crucial for success.

Enacting Sustainable Practices, Pharmacist Provider Status Is Growing

Growing demand for sustainable practices in the pharmaceutical industry, rising recognition of pharmacist provider status, rapid technological shifts in the FDA's device unit, strategic alliances in ADC development, and an evolving oncology policy landscape emphasise the need for adaptation and innovation.

Bristol Myers' Earnings Surpass Forecasts with Strong Drug Sales

Bristol Myers Squibb's third-quarter earnings surpassed expectations, driven by strong sales of older drugs like Eliquis and Revlimid, alongside newer products such as Camzyos and Breyanzi. The company's revenue rose 8% to $11.89 billion, prompting an increase in its annual profit forecast to 75-95 cents per share.

TODAY’S EVENTS 📆

Webinar with Roderick Jefferson - The Godfather of Sales

📅Wednesday, November 13

⏰18:00 - 19:00 GMT.

Support your sales team beyond onboarding with "Ever-Boarding." Join expert Roderick Jefferson to learn how AI can personalize coaching, foster continuous learning, and accelerate sales ramp-up through data-driven processes.